Accelerating the translation of digital medicines manufacturing into industrial application.
Funding: £
Duration: Apr 22 - Mar 26
Funder: UKRI Made Smarter Innovation
Academic partners:
The Digital Medicines Manufacturing Research Centre project (known as DM²) has delivered a step-change in CMAC’s digital capability for advanced manufacturing. Over its duration, the project has built powerful digital tools to advance automation, modelling and data-driven innovation ready to shape.
Project overview
DM² addressed a critical challenge facing medicines development: how to translate digital and data‑driven research into practical, scalable manufacturing improvements that industry can adopt with confidence. While digital tools were advancing rapidly, their integration into real‑world pharmaceutical development remained fragmented, limiting impact on speed, robustness and sustainability.
This was important to CMAC, industry and the wider sector because UK and global medicines manufacturing faces increasing pressure to deliver treatments faster, more sustainably and with greater resilience. Building on evidence from DM² Phase 1 (Apr 22 - Mar 25), which demonstrated significant reductions in development time and waste, the DM² Accelerator (Apr 25 -Mar 26) focused on turning digital capability into usable, transferable assets, while strengthening skills and lowering adoption barriers for pharma and SMEs.
Strategically, the programme aligned directly with CMAC’s priorities to advance cyber‑physical research infrastructure, deepen industrial translation and support national advanced manufacturing ambitions. By integrating data, automation and human‑centred design across the CMC DataFactories®, the project enabled more connected, model‑driven ways of working and accelerated progress towards responsive, sustainable manufacturing.
Through industry co‑creation, demonstration trials and technology transfer packages, DM² strengthened CMAC’s research excellence, expanded its digital manufacturing platform, and established clear pathways from research to industrial practice. In doing so, it demonstrated what smarter, faster and more agile medicines manufacturing can look like in practice, positioning CMAC and its partners at the forefront of digital CMC innovation.
Objectives:
Advance integrated, autonomous research environments by connecting data, models, automation and physical facilities into cohesive, digital‑first workflows.
Accelerate industrial translation and commercial readiness through user‑led design, demonstration trials and the creation of transferable technology packages.
Build digital skills and capability across pharmaceutical manufacturing, supporting both current workforce upskilling and future talent.
Enable more sustainable and responsive medicines manufacturing, aligned with UK advanced manufacturing ambitions and industry needs.
Areas of focus
-
The DM² Accelerator focused on strengthening CMAC’s ability to translate digital research into industrially relevant manufacturing practice. Specifically, the project included: Advancement of CMAC’s cyber‑physical research infrastructure (CPRI), building on DM² Phase 1 and integrating digital, data and physical manufacturing capabilities across the CMC DataFactories®.
-
Development and integration of advanced digital workflows, including interoperable data structures, modelling, automation and orchestration across crystallisation, tableting and connected manufacturing processes.
-
Demonstration and validation through industry‑relevant case studies and trials, co‑created with pharmaceutical partners to test usability, readiness and value in realistic settings.
-
Creation of translation and adoption assets, such as technology transfer packages, standardised architectures, workflows and user requirements to support uptake by large pharma and SMEs.
-
Skills development and upskilling in digital pharmaceutical manufacturing for researchers, industry partners and the wider sector.
-
Support for sustainability and responsiveness in manufacturing, aligned with UK advanced manufacturing ambitions, through digital‑first, data‑enabled approaches.
What we delivered
-
The project created a suite of tools that strengthen research, process design and decision-making:
Predictive models for drug substance and product processes
Real-time process analytics
Digital twins and simulation environments
Automated data pipelines
-
Our CMC DataFactories are enabling 24/7 high‑throughput experimentation and reducing manual intervention including:
Integration of autonomous workflows
Automated experimental planning
Enhanced data capture and monitoring
-
The project delivered new modelling tools and techniques:
New mechanistic and data-driven models
Improved process design and optimisation
Model‑based control and risk assessment
-
DM2 worked in partnership with industry collaborators to validate tools, share data and accelerate digital transformation across the sector.
Co‑development with industrial partners
Validation in real manufacturing settings
Shared datasets and aligned workflows
Commercialisation pathway development via OpenCMC (University of Strathclyde spin‑out)
-
We’ve created tools to build a digitally‑enabled workforce.
Training modules for researchers and partners
Upskilling across automation, modelling, and digital literacy
Cross-team learning embedded into CMAC culture
CMAC SkillsFactory, an online learning platform
Research highlights
-
Knowledge Graph–enabled digital CMC
Delivered an interoperable, FAIR data backbone connecting models, experiments and workflows across multiple CMC DataFactories®, enabling semantically searchable and reusable digital research at scale.
-
Integrated cyber‑physical manufacturing workflows
Demonstrated end‑to‑end, model‑driven workflows linking crystallisation, tableting and analytics, showing how digital and physical systems can operate together in real time.
-
Advanced, industry‑relevant DataFactory capability
Upgraded and extended our Tableting and Crystallisation Screening CMC DataFactories® to higher technology readiness, supporting potent compounds and industrial trial conditions.
-
Human‑centric digital manufacturing interfaces
Embedded XR dashboards and natural‑language tools to improve accessibility, insight and usability of complex digital manufacturing systems for researchers and industry users.
-
Validated digital translation through real case studies
Delivered multi‑partner demonstration trials, including a Dexamethasone case study, proving digital CMC approaches can accelerate decision‑making, robustness and sustainability in practice.
Impact highlights
41 papers published
814 people upskilled
50-80% waste reduction evidenced
> £4M co-investment from industry
6 industry trials delivered
What’s next?
Work from the DM² project is being taken forward through continued development of the CMC DataFactories® as connected digital manufacturing platforms, feeding directly into MediForge to support end‑to‑end, translation‑focused medicines development.
Validated workflows, data architectures and design assets are progressing towards industrial uptake through OpenCMC, enabling scalable deployment while continuing to support skills development and collaborative research.
Words from our collaborators
“It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more. Or maybe you have a creative project to share with the world. Whatever it is, the way you tell your story online can make all the difference.”
— Quote Source
“It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more. Or maybe you have a creative project to share with the world. Whatever it is, the way you tell your story online can make all the difference.”
— Quote Source
“It all begins with an idea. Maybe you want to launch a business. Maybe you want to turn a hobby into something more. Or maybe you have a creative project to share with the world. Whatever it is, the way you tell your story online can make all the difference.”
— Quote Source
Get in touch
